CTLA4 and melanoma: Early studies reported that greater baseline gut microbiota richness and diversity were associated with improved responses to ICIs, including anti-CTLA-4 and anti-PD-1 therapies in melanoma and epithelial cancers, while antibiotic use was linked to diminished clinical benefit (58–61).